Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)
China
· Delayed Price · Currency is CNY 3.350
+0.050 (1.52%)
Apr 30, 2026, 11:54 AM CST
SHE:002390 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 5,620 | 6,000 | 6,436 | 6,331 | 6,441 | Upgrade
|
| Other Revenue | - | 32.17 | 24.98 | 19.36 | 30.76 | Upgrade
|
| Revenue | 5,620 | 6,032 | 6,461 | 6,350 | 6,472 | Upgrade
|
| Revenue Growth (YoY) | -6.84% | -6.63% | 1.75% | -1.88% | 10.71% | Upgrade
|
| Cost of Revenue | 4,628 | 5,000 | 5,240 | 5,133 | 5,119 | Upgrade
|
| Gross Profit | 991.73 | 1,032 | 1,221 | 1,217 | 1,352 | Upgrade
|
| Selling, General & Admin | 609.66 | 669.9 | 737.84 | 814.14 | 766.62 | Upgrade
|
| Research & Development | 5.8 | 4.59 | 4.67 | 1.21 | 1.94 | Upgrade
|
| Other Operating Expenses | 33.35 | 25.01 | 22.57 | 28.19 | 28.7 | Upgrade
|
| Operating Expenses | 648.81 | 749.07 | 830.01 | 884.14 | 823.94 | Upgrade
|
| Operating Income | 342.92 | 282.84 | 391.05 | 332.82 | 528.56 | Upgrade
|
| Interest Expense | - | -23.54 | -39.7 | -51.79 | -100.19 | Upgrade
|
| Interest & Investment Income | 19.74 | 10.76 | 22.13 | 50.97 | 17.92 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0 | 0 | 0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -110.53 | -18.96 | 11.01 | -22.76 | -4.47 | Upgrade
|
| EBT Excluding Unusual Items | 252.12 | 251.1 | 384.49 | 309.25 | 441.82 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.48 | -2.29 | 0.02 | -0 | -0.42 | Upgrade
|
| Asset Writedown | -21.67 | -1.11 | -0.56 | -2.13 | -4.04 | Upgrade
|
| Other Unusual Items | - | -62.2 | 12.08 | 6.28 | -16.23 | Upgrade
|
| Pretax Income | 229.96 | 185.5 | 396.02 | 313.39 | 421.12 | Upgrade
|
| Income Tax Expense | 38.17 | 29.81 | 42.25 | 45.14 | 47.17 | Upgrade
|
| Earnings From Continuing Operations | 191.8 | 155.69 | 353.77 | 268.26 | 373.96 | Upgrade
|
| Minority Interest in Earnings | -71.51 | -54.31 | -66.54 | -43.88 | -101.09 | Upgrade
|
| Net Income | 120.29 | 101.38 | 287.23 | 224.37 | 272.87 | Upgrade
|
| Net Income to Common | 120.29 | 101.38 | 287.23 | 224.37 | 272.87 | Upgrade
|
| Net Income Growth | 18.65% | -64.70% | 28.02% | -17.77% | 57.25% | Upgrade
|
| Shares Outstanding (Basic) | 1,897 | 2,028 | 1,915 | 1,870 | 1,819 | Upgrade
|
| Shares Outstanding (Diluted) | 1,897 | 2,028 | 1,915 | 1,870 | 1,819 | Upgrade
|
| Shares Change (YoY) | -6.43% | 5.89% | 2.41% | 2.79% | 15.32% | Upgrade
|
| EPS (Basic) | 0.06 | 0.05 | 0.15 | 0.12 | 0.15 | Upgrade
|
| EPS (Diluted) | 0.06 | 0.05 | 0.15 | 0.12 | 0.15 | Upgrade
|
| EPS Growth | 26.80% | -66.67% | 25.00% | -20.00% | 36.36% | Upgrade
|
| Free Cash Flow | 647.11 | 510.1 | 654.84 | 432.02 | 204.21 | Upgrade
|
| Free Cash Flow Per Share | 0.34 | 0.25 | 0.34 | 0.23 | 0.11 | Upgrade
|
| Dividend Per Share | - | 0.060 | 0.060 | 0.060 | 0.060 | Upgrade
|
| Gross Margin | 17.65% | 17.11% | 18.90% | 19.16% | 20.90% | Upgrade
|
| Operating Margin | 6.10% | 4.69% | 6.05% | 5.24% | 8.17% | Upgrade
|
| Profit Margin | 2.14% | 1.68% | 4.45% | 3.53% | 4.22% | Upgrade
|
| Free Cash Flow Margin | 11.52% | 8.46% | 10.13% | 6.80% | 3.16% | Upgrade
|
| EBITDA | 540.18 | 491.06 | 619.72 | 567.89 | 767.42 | Upgrade
|
| EBITDA Margin | 9.61% | 8.14% | 9.59% | 8.94% | 11.86% | Upgrade
|
| D&A For EBITDA | 197.27 | 208.22 | 228.67 | 235.06 | 238.86 | Upgrade
|
| EBIT | 342.92 | 282.84 | 391.05 | 332.82 | 528.56 | Upgrade
|
| EBIT Margin | 6.10% | 4.69% | 6.05% | 5.24% | 8.17% | Upgrade
|
| Effective Tax Rate | 16.60% | 16.07% | 10.67% | 14.40% | 11.20% | Upgrade
|
| Revenue as Reported | - | 6,032 | 6,461 | 6,350 | 6,472 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.